Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia - PubMed (original) (raw)
Comparative Study
. 2006 Feb 3;1071(1):75-80.
doi: 10.1016/j.brainres.2005.11.072. Epub 2006 Jan 17.
Affiliations
- PMID: 16413513
- DOI: 10.1016/j.brainres.2005.11.072
Comparative Study
Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia
Hideyuki Yamada et al. Brain Res. 2006.
Abstract
The purpose of this study was to determine whether iganidipine, nimodipine and lomerizine, potentially useful calcium channel blockers for ophthalmic treatment, have direct retinal neuroprotective effects against hypoxic damage in experimental in vitro model. We used purified retinal ganglion cells (RGCs) from newborn rats. RGCs were incubated in controlled-atmosphere incubator in which oxygen levels were reduced to 5% normal partial pressure and cell viability was assessed. We also examined the effect of calcium channel blockers on the calcium ion concentration in RGC under hypoxic stress by calcium imaging. Iganidipine, nimodipine and lomerizine (0.01-1 microM) increased the RGC viability. Increase in intra-RGC calcium ion concentration by hypoxic damage was reduced by these calcium channel blockers. In conclusion, iganidipine, nimodipine and lomerizine were effective against hypoxic RGC damage in vitro. This neuroprotective effect was thought to be mediated by blocking calcium ion influx into RGC. These findings suggest that iganidipine, nimodipine and lomerizine have a direct neuroprotective effect against RGC damage related to hypoxia.
Similar articles
- Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of beta-adrenergic antagonists.
Chen YN, Yamada H, Mao W, Matsuyama S, Aihara M, Araie M. Chen YN, et al. Brain Res. 2007 May 7;1148:28-37. doi: 10.1016/j.brainres.2007.02.027. Epub 2007 Feb 22. Brain Res. 2007. PMID: 17368577 - Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine.
Fitzgerald M, Payne SC, Bartlett CA, Evill L, Harvey AR, Dunlop SA. Fitzgerald M, et al. Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5456-62. doi: 10.1167/iovs.09-3717. Epub 2009 May 27. Invest Ophthalmol Vis Sci. 2009. PMID: 19474405 - A new calcium channel antagonist, lomerizine, alleviates secondary retinal ganglion cell death after optic nerve injury in the rat.
Karim Z, Sawada A, Kawakami H, Yamamoto T, Taniguchi T. Karim Z, et al. Curr Eye Res. 2006 Mar;31(3):273-83. doi: 10.1080/02713680500536647. Curr Eye Res. 2006. PMID: 16531285 - Neuroprotective properties of calcium-channel blockers.
Zornow MH, Prough DS. Zornow MH, et al. New Horiz. 1996 Feb;4(1):107-14. New Horiz. 1996. PMID: 8689265 Review. - Clinical potential of lomerizine, a Ca2+ channel blocker as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage.
Hara H, Toriu N, Shimazawa M. Hara H, et al. Cardiovasc Drug Rev. 2004 Fall;22(3):199-214. doi: 10.1111/j.1527-3466.2004.tb00141.x. Cardiovasc Drug Rev. 2004. PMID: 15492768 Review.
Cited by
- Neuroprotection in Glaucoma.
Doozandeh A, Yazdani S. Doozandeh A, et al. J Ophthalmic Vis Res. 2016 Apr-Jun;11(2):209-20. doi: 10.4103/2008-322X.183923. J Ophthalmic Vis Res. 2016. PMID: 27413504 Free PMC article. Review. - Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity.
Ishii M, Iizuka R, Kiuchi Y, Mori Y, Shimizu S. Ishii M, et al. Mol Cell Biochem. 2011 Dec;358(1-2):1-11. doi: 10.1007/s11010-011-0913-3. Epub 2011 Jun 9. Mol Cell Biochem. 2011. PMID: 21656126 - REVIEW: An approach for neuroprotective therapies of secondary brain damage after excitotoxic retinal injury in mice.
Ito Y, Shimazawa M, Hara H. Ito Y, et al. CNS Neurosci Ther. 2010 Oct;16(5):e169-79. doi: 10.1111/j.1755-5949.2010.00176.x. Epub 2010 Jun 11. CNS Neurosci Ther. 2010. PMID: 20553302 Free PMC article. Review. - Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation.
Shalaby U. Shalaby U. Jpn J Ophthalmol. 2017 Mar;61(2):169-178. doi: 10.1007/s10384-016-0490-9. Epub 2016 Dec 10. Jpn J Ophthalmol. 2017. PMID: 27943089 Clinical Trial. - Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance.
Kuo CY, Liu CJ. Kuo CY, et al. J Pers Med. 2022 Nov 10;12(11):1884. doi: 10.3390/jpm12111884. J Pers Med. 2022. PMID: 36579616 Free PMC article. Review.